GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » Momentum Rank

Bright Minds Biosciences (XCNQ:DRUG) Momentum Rank : 3 (As of Apr. 30, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Momentum Rank?

Bright Minds Biosciences has the Momentum Rank of 3.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of Bright Minds Biosciences's Momentum Rank

For the Biotechnology subindustry, Bright Minds Biosciences's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bright Minds Biosciences's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Momentum Rank falls into.


;
;

Bright Minds Biosciences Momentum Rank Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Bright Minds Biosciences Business Description

Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Executives
Jan Torleif Pedersen Director
Nils Bottler Director
Ryan Cheung Senior Officer
Jeremy Fryzuk Director
Alan Kozikowski 10% Security Holder, Director, Senior Officer
Ian Mcdonald Director